Business Wire

NILIT

26.8.2024 21:03:49 CEST | Business Wire | Press release

Share
Samsara Eco and NILIT Team up to Build World-First Nylon 6,6 Recycling Facility

Samsara Eco, the enviro-tech innovator and NILIT, the world’s leader in the production of nylon 6,6 for apparel, have announced plans to explore investment and construction of a nylon 6,6 textile-to-textile recycled polymer production site in South East Asia to help close the loop on nylon 6,6.

Roughly 4 million tonnes of nylon 6,6 is created every year, it is one of the most widely used fibers in the performance apparel and fashion industries. However, it is notoriously difficult to recycle and when blended with other fibres like spandex, it increases the challenge. Together, Samsara Eco and NILIT are seeking to address this issue head-on.

Aiming to be operational by late 2026, the anticipated facility will be uniquely capable of recycling textile waste, producing high-quality recycled nylon 6,6 polymers, for textile brands and manufacturers to seamlessly use in their existing supply chains to create new textile fabrics, infinitely.

“Our vision is to deliver climate repair through infinite recycling. One of the ways we’re achieving this is by creating the first circular pathway for nylon 6,6. Discarded clothing made from nylon 6,6 such as activewear, and even products like car interiors, typically end up in landfill or are incinerated at the end of life, which has dire consequences for our planet,” said Paul Riley, CEO and Founder of Samsara Eco.

Sarah Cook, Chief Commercial and Operations Officer of Samsara Eco also commented on the agreement: “By working with NILIT, we can reverse this trend and give apparel a new life. The MoU agreement is an important step to help brands and the world advance nylon 6,6 circularity and reduce plastic waste. We’re proud to be exploring a pilot recycling facility with NILIT, setting a precedent of what’s possible for future partners globally.”

“NILIT’s partnership with Samsara Eco is a critical step in our multi-pronged strategy to provide the apparel market with premium nylon 6,6 products that have lower environmental impact,” explained Ilan Melamed, NILIT General Manager. “Implementing textile-to-textile recycling solutions will substantially decrease global carbon emissions and reduce the 92 million tonnes of textile waste added to landfills annually. Together, NILIT and Samsara Eco have the potential to produce infinitely recycled nylon 6,6 that delivers outstanding fabric quality and performance while benefitting the planet.”

EosEco™ is the world's first technology to infinitely recycle nylon 6,6 by combining biophysics, chemistry, biology and computer science (such as AI) to create a family of plastic-eating enzymes. The enzymes break down plastic waste, including textiles made from nylon 6,6 into raw materials, which are then seamlessly integrated into existing manufacturing processes to create a truly closed loop. EosEco™ can recycle a breadth of feedstock inputs, including coloured and blended textiles like nylon 6,6 with spandex. EosEco™, together with NILIT’s unique polymerization, spinning and technology will be able to create premium recycled Nylon 6, 6 yarn for global consumption.

About NILIT

Celebrating 50 years of excellence, NILIT offers the broadest collection of premium sustainable Nylon 6,6 yarns designed to empower the apparel industry’s shift to a more sustainable position. Operating internationally, NILIT is the global leader in Nylon 6,6 yarns for apparel, dedicated to creating innovative and sustainable solutions that advance the textile industry.

NILIT will add Samsara Eco’s EosEco™ produced yarn to its innovative SENSIL® preferred portfolio of products which is manufactured according to NILIT’s Total Product Sustainability criteria. These responsible yarns give designers the beautiful, environmentally considerate performance fabrics they need to create apparel collections that respond to consumer demands.

About Samsara Eco

Samsara Eco is using advanced, enzymatic recycling to end plastic pollution. With breakthrough science, Samsara Eco has developed a new way to break plastic down to its core molecules, which can then be used to recreate brand-new plastic, again and again. Its patented technology, EosEco™ is a first-of-its-kind process that is genuinely better for the planet.

Samsara Eco’s community is united by the shared mission to divert plastic from our landfills and oceans, and eliminate the need to create plastic from fossil fuels, (whether it’s for the bottles we drink from or the clothes we wear) for a cleaner and more sustainable future.

In partnership with the Australian National University (ANU), Samsara Eco launched in 2020 with the backing of Main Sequence and Woolworths Group’s W23. It has raised more than AUD $160M in funding from local and global investors including Breakthrough Victoria, DCVC, Hitachi, lululemon, Temasek, Wildcard Ventures, Wollemi Capital and more.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240820332060/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release

Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng

vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release

Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye